scispace - formally typeset
L

Leondios G. Kostrikis

Researcher at University of Cyprus

Publications -  86
Citations -  7580

Leondios G. Kostrikis is an academic researcher from University of Cyprus. The author has contributed to research in topics: Population & Genotype. The author has an hindex of 39, co-authored 82 publications receiving 7154 citations. Previous affiliations of Leondios G. Kostrikis include Aaron Diamond AIDS Research Center & National and Kapodistrian University of Athens.

Papers
More filters
Journal ArticleDOI

Methodologies of Primary HPV Testing Currently Applied for Cervical Cancer Screening

TL;DR: This review presents the current HPV testing methodologies, their application in organized population-based cervical cancer screening programs based on the most recent European guidelines, and their implementation status in countries in Europe.
Journal ArticleDOI

HIV-1 Infection in Cyprus, the Eastern Mediterranean European Frontier: A Densely Sampled Transmission Dynamics Analysis from 1986 to 2012

TL;DR: Young and drug-naïve HIV-1-infected individuals in Cyprus are driving the dynamics of the local HIV- 1 epidemic, and this methodology for analyzing densely sampled transmissiondynamics is applicable to other geographic regions to implement effective HIV-2 prevention strategies in local settings.
Journal ArticleDOI

Evidence for recent selection of the CCR5-delta 32 deletion from differences in its frequency between Ashkenazi and Sephardi Jews.

TL;DR: The results suggest that a positive selection process for ccr5-δ32 should have occurred in northern europe at most a 1000 years ago, after the ashkenazi jews separated from their sephardi kin and moved to north europe.
Journal ArticleDOI

Changes in T cell receptor excision DNA circle (TREC) levels in HIV type 1-infected subjects pre- and post-highly active antiretroviral therapy.

TL;DR: TREC values, which likely represent a simple indicator of naive T-lymphocyte reserve, may be a clinically useful marker for long-term prognosis of HIV-1 infection and for immune reconstitution after successful HAART.